Elevated levels of the tumor marker S100B are observed in malignant melanoma, and this EF-hand-containing protein was shown to directly bind wild-type (wt) p53 in a Ca-dependent manner, dissociate the p53 tetramer, and inhibit its tumor suppression functions. Likewise, inhibiting S100B with small interfering RNA (siRNA) is sufficient to restore wild-type p53 levels and its downstream gene produ...

BACKGROUND S100B protein and Neuron Specific Enolase (NSE) can increase due to brain cell damage and/or increased permeability of the blood-brain-barrier. Elevation of these proteins has been shown after various neurological diseases with cognitive dysfunction. Delirium is characterized by temporal cognitive deficits and is an important risk factor for dementia. The aim of this study was to com...

BACKGROUND S100B (S100beta) is a member of the S100 family of small calcium-binding proteins: members of this family contain two helix-loop-helix calcium-binding motifs and interact with a wide range of proteins involved mainly in the cytoskeleton and cell proliferation. S100B is a neurite-extension factor and levels of S100B are elevated in the brains of patients with Alzheimer's disease or Do...

BACKGROUND An understanding of the kinetics of a biomarker is essential to its interpretation. Despite this, little kinetic modelling of blood biomarkers can be found in the literature. S100b is an astrocyte related marker of brain injury used primarily in traumatic brain injury (TBI). Serum levels are expected to be the net result of a multi-compartmental process. The optimal sample times for ...

The acknowledgement of risks for traumatic brain injury in American football players has prompted studies for sideline concussion diagnosis and testing for neurological deficits. While concussions are recognized etiological factors for a spectrum of neurological sequelae, the consequences of sub-concussive events are unclear. We tested the hypothesis that blood-brain barrier disruption (BBBD) a...

S100B, a calcium-dependent protein produced by astroglial cells in the central nervous system (CNS) and by chondrocytes, functions as both a neurotrophin and neurotoxin. It has a half-life in the systemic circulation of approximately six hours. We examined whether serum levels of S100B would be predictive of intracranial injury (ICI) in children, as detected by cranial computed tomography (CT),...

Introduction: S100B is a protein released from astrocytes, which controls neuroglial relationship and probably plays a role in memory and synaptic plasticity. Study of the functional relationship between astrocytes and neurons is of great importance. The present study was conducted to evaluate the effect of S100B infusion into the CA1 region of the hippocampus, on memory performance in male ...

BACKGROUND An easily accessible and valid surrogate marker for interventional stroke trials is needed. OBJECTIVE To investigate the usefulness of various S100B serum measures to predict long-term outcome and infarct volume in patients with acute stroke. DESIGN Inception cohort study. SETTING Tertiary care university hospital. PATIENTS Thirty-nine patients (mean +/- SD age, 69.1 +/- 11.5...

S100B binds tightly to a 12-amino acid peptide derived from heterodimeric capping protein. In native intact capping protein, this sequence is in the C terminus of the alpha-subunit, which is important for capping the actin filament. This C-terminal region is proposed to act as a flexible "tentacle," extending away from the body of capping protein in order to bind actin. To this hypothesis, we a...

Objective: Use of biochemical markers of cerebral ischemia is a newly favored approach for early diagnosis of ischemic stroke. Our aim was to establish the sensitivity and specificity of ischemia-modified albumin (IMA) in acute ischemic stroke and to compare it with S100b and neuron-specific enolase (NSE). We also intended to investigate the usefulness of a panel composed of these three biomark...